Practicing Precision in ALK and ROS1 Rearrangement Positive NSCLC: Testing, Targets, and Treatments - a podcast by ReachMD

CME credits: 1.00

Valid until: 24-08-2022

Claim your CME credit at https://reachmd.com/programs/cme/practicing-precision-alk-and-ros1-rearrangement-positive-nsclc-testing-targets-and-treatments/12757/

Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.

The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.

This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD